A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This Phase II randomized study is to explore the efficacy and safety of Furmonertinib
combined with radiotherapy for non-small cell lung cancer with oligoprogression after
first-line EGFR-TKI therapy.